Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sucampo Pharmaceuticals has reported positive top-line results from Phase III trial of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.
Subscribe to our email newsletter
In the multicenter, open-label extension study reported no serious adverse events that were considered drug-related.
The most common adverse events that arose during the trial were diarrhea (9.6%), nausea (8.9%), upper respiratory infection (6.4%) and back pain (5.2%).
The adverse events that were considered treatment-related (greater than 2%) were nausea (5.0%) and diarrhea (4.6%).
Sucampo chair, CEO and CSO Ryuji Ueno said the long term safety profile and efficacy were observed in this Phase 3 trial of lubiprostone in OBD.
"With these data and those of the previously completed phase 3 trials, we now have all the necessary data for submission and are preparing to file the sNDA mid-year with a request for priority review," Ueno added.